In triple-negative breast cancer, CREB was identified as a key transcription factor regulating RAS protein activator-like 2 (RASAL2), a crucial factor associated with resistance to platinum-based chemotherapy 53. This evidence concerns the gene RASAL2 and triple-negative breast carcinoma.